Shareholders approve Eliem-Tenet merger; closing expected June 27, 2024

Climb Bio, Inc.

Share Issuance Proposal passed: 26,311,239 for, 3,253 against; disinterested approval 12,655,083 for.
Directors Andrew Levin and Liam Ratcliffe elected to board until 2027.
PricewaterhouseCoopers ratified as independent auditor for FY2024.
Acquisition of Tenet Medicines and concurrent PIPE expected to close on or about June 27, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.